

Title (en)
SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY

Title (de)
SELEKTIN- ODER GALECTIN-ANTAGONISTEN ZUR BEHANDLUNG DES CYTOKINFREISETZUNGSSYNDROMS UND CRS-INDUZIERTER NEUROTOXIZITÄT

Title (fr)
ANTAGONISTES DE LA SÉLECTINE OU DE LA GALECTINE POUR LE TRAITEMENT DU SYNDROME DE LIBÉRATION DE LA CYTOKINE ET DE LA NEUROTOXICITÉ INDUITE PAR LE CRS

Publication
EP 3911307 A1 20211124 (EN)

Application
EP 20710319 A 20200114

Priority
• US 201962792231 P 20190114
• US 2020013544 W 20200114

Abstract (en)
[origin: WO2020150263A1] Methods and compounds for the treatment and/or prevention of CRS and/or CRS-induced neurotoxicities using at least one selectin antagonist are disclosed. The disclosed methods and compounds use at least one of the disclosed antagonists to target and reduce cytokine expression and/or endothelial activation to treat and/or prevent CRS and/or CRS-related conditions such as CRS-induced neurotoxicities.

IPC 8 full level
A61K 31/00 (2006.01); **A61K 31/702** (2006.01); **A61K 31/7042** (2006.01); **A61K 31/7048** (2006.01); **A61K 31/7052** (2006.01); **A61K 31/706** (2006.01); **A61K 31/715** (2006.01); **A61K 45/06** (2006.01); **A61P 25/00** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 31/00 (2013.01); **A61K 31/702** (2013.01); **A61K 31/7042** (2013.01); **A61K 31/7048** (2013.01); **A61K 31/7052** (2013.01); **A61K 31/706** (2013.01); **A61K 31/715** (2013.01); **A61K 45/06** (2013.01); **A61P 25/00** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)
See references of WO 2020150263A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020150263 A1 20200723; EP 3911307 A1 20211124

DOCDB simple family (application)
US 2020013544 W 20200114; EP 20710319 A 20200114